Prof. Murali Mohan Yallapu

University of Texas Rio Grande Valley, UTRGV, USA
Staff Scientist

E-mail: [email protected]

Qualifications

2001 Ph.D., Sri Krishnadevaraya University

1997 M.Sc., Sri Krishnadevaraya University

1993 B.Sc., Sri Krishnadevaraya University

Publications (Selected)

1. Yang, B., Sedano, M. J., Perez, K., et al. (2026). RNA therapeutics: current status and future directions. Signal Transduction and Targeted Therapy, 11(1), Article 409.
2. Yamaguchi, A., Coll, R. P., Wang, J., et al. (2026). Glycoprotein Mucin 13 expression as a theranostic target in colorectal cancer. Clinical Cancer Research, 32(16), 3655–3667.
3. Ghali, E. N. H. K., Shim, L., Baru, R., et al. (2026). Miconazole as a repurposed anticancer candidate for prostate cancer. ACS Omega, 11(31), 45913–45930.
4. Dhasmana, A., Dhasmana, S., Khan, S., et al. (2026). Utilization of CEACAM7 as a novel diagnostic biomarker of pancreatic cancer. Journal of Clinical Oncology, 44(16_suppl), Article e16421.
5. Ghali, E. N. H. K., Shim, L., Tiwari, R., et al. (2026). Miconazole as a repurposed therapeutic candidate for prostate cancer. Journal of Clinical Oncology, 44(16_suppl), Article e17130.
6. Tiwari, R., Kolli, M., Ghali, E. N. H. K., et al. (2026). Inhalable polyphenolic-based nanoparticles for localized lung cancer treatment. Journal of Clinical Oncology, 44(16_suppl), Article e20758.
7. Singh, S., Vidaurri, S., Perez, A., et al. (2026). Enhanced recovery of high-quality DNA from limited FFPE tissue for advancing cancer genomics. Scientific Reports, 16(1), Article 23521.
8. Phillip, A., Karithara, A., Chauhan, S. C., & Yallapu, M. M. (2026). Emerging near-infrared targeted imaging pharmaceutics for ovarian cancer. Pharmaceutics, 18(5), Article 574.
9. Nayek, U., Sharma, T., Kashyap, V. K., et al. (2026). Scope of nanobodies in hepatopancreatobiliary oncology. Drug Discovery Today, 31(3), Article 104666.
10. Dhasmana, A., Dhasmana, S., Baru, R., et al. (2026). MUC13-associated molecular interactome in pancreatic cancer. Computational and Structural Biotechnology Journal, 35(1), Article 0056.
11. Singh, S., Ledezma, V., Vidaurri, S., et al. (2026). GPER modulates microbial liver gut axis and suppresses hepatocellular carcinoma. Cancer Research, 86(8), Article LB004.
12. Vidaurri, S., Singh, S., Ledezma, V., et al. (2026). GPER as an actionable target in endocrine resistant breast cancer. Cancer Research, 86(8), Article LB475.
13. Dhasmana, A., Dhasmana, S., Baru, R., et al. (2026). Clinicopathological and molecular significance of MUC13 in HCC. Cancer Research, 86(7), Article 2726.
14. Dhasmana, S., Dhasmana, A., Singh, S., et al. (2026). Influence of transgenic MUC13 expression on gut microbiota and chemokine profile. Cancer Research, 86(7), Article 2876.
15. Ghali, E. N. H. K., Shim, L., Tiwari, R., et al. (2026). Miconazole induces cell cycle arrest and apoptosis in prostate cancer cells via a p53-mediated pathway: A drug repurposing strategy. Cancer Research, 86(7), Article 4465.
16. Kashyap, V. K., Nagesh, P. K. B., Wang, Q., et al. (2026). Next-generation sabizabulin nanoformulation for cervical cancer treatment. Cancer Research, 86(7), Article 6396.
17. Malik, S., Sikander, M., Zubieta, D., et al. (2026). Oncogenic cooperation of MUC13 and NDRG1 signaling in liver cancer. Cancer Research, 86(7), Article 309.
18. Perez, K., Delgadillo, F. M., Dhandayuthapani, S., et al. (2026). Analysis of metabolic dysfunction-associated transcripts in hepatocellular carcinoma. Cancer Research, 86(7), Article 5906.
19. Sikander, M., Malik, S., Baru, R., et al. (2026). Prolonged radiation exposure alters cellular proteome network in human hepatocellular carcinoma cells. Cancer Research, 86(7), Article 7378.
20. Kashyap, V. K., Sharma, B. P., Singh, H. N., et al. (2026). Bioinformatics analysis of TRPV1 expression and its role in hepatocellular carcinoma prognosis. Discover Oncology, 17(1), Article 698.
21. Gao, Y. X., Chen, W., Zarogoulidis, P., et al. (2026). Multiomics and experimental validation reveal theophylline's mechanism targeting IL1A/ACTB/TLR4 and identify synergistic drugs in hepatocellular carcinoma. Journal of Pharmacology and Experimental Therapeutics, 393(3), Article 103836.
22. Ahmad, M., Alvi, S. S., Ahsan, H., et al. (2026). Ubiquitination of oncogenic mutant p53 via attenuation of ribosome biogenesis machinery effectively inhibits pancreatic tumor growth. Molecular Cancer Therapeutics, 25(2), 257–271.

Profile Details

https://www.utrgv.edu/school-of-medicine/directory/index.htm?department=integratedcancerresearchcore
https://scholar.google.com/citations?user=p8k7iq0AAAAJ&hl=en

WOS ResearchID: F-5323-2010